BACKGROUND:Number of experimental and clinical studies have shown that stem celltransplantation can establish new blood vessels and improve heart function instead of necrotic myocardium, to significantly improved clinical symptoms and prognosis of cardiovascular disease patients.
OBJECTIVE:To observe the safety of human umbilical cord blood mononuclear cells transplantation in patients with coronary heart disease and heart failure.
METHODS:A total of 12 patients with coronary heart disease and heart failure (acute myocardial infarction and heart failure in six cases, old myocardial infarction and heart failure in six cases) were enrol ed in this study. Patients were treated on the basis of standard medication and percutaneous coronary intervention. The coronary pathway was established via a percutaneous catheter, and suspension of cord blood mononuclear cells was injected through microcatheter into the distal artery. Routine blood test was carried out at 1 week after celltransplantation, blood routine, liver function, kidney function, C-reactive protein, IgA, IgG were compared preoperatively and postoperatively.
RESULTS AND CONCLUSION:The incidence of adverse reactions in cord blood stem celltransplantation was 8.3%, including one case of fever. No micro-embolism occurred. During 1-week fol ow-up, no graft-versus-host disease appeared. After celltransplantation, there were no significant changes in blood routine, liver function, kidney function, C-reactive protein, IgA, IgG. These findings indicate umbilical cord blood monomuclear cells transplantation is safe in a short term for patients with coronary heart disease and heart failure.

BACKGROUND: Transplantation of the human umbilical cord blood mononuclear cells (HUCBCs) have received increasing attention, as a promising candidate for the cellular transplantation, but the majority of the existing studies are basic research.OBJECTIVE: To report a patient of extensive anterior-wall acute myocardial infarction with cardiogenic shock and severe heart failure, after treatment of HUCBCs transplantation. METHODS: A 73-year-old female patient with cardiogenic shock and severe heart failure after extensive anterior-wall acute myocardial infarction was treated with percutaneous coronary intervention (three scaffolds implantation) and medications, and she still appeared the symptoms of congestive heart failure, such as severe recurrent dyspnea. 2.4 × 108 HUCBCs (50 mL cell suspension) was injected into the infarcted myocardium through the left anterior descending artery by using coronary micro-guide catheter.RESULTS AND CONCLUSION: The patient reported profound clinical benefit including improvement of heart-failure-associated symptoms after the transplantation. Notably the patient did not experience the cell transplant-related side effects during 4 months of follow-up. The ejection fraction increased from 22% before the transplantation to 53% at 21 days after the transplantation. The B-type natriuretic peptide decreased from 1 730 ng/L before the transplantation, 854 ng/L after the transplantation to 264 ng/L at 21 days after the transplantation. The patient did not appear the symptoms of congestive heart failure, including dyspnea, chest distress and hypodynamia, she returned to daily activity at 4 months of follow-ups. Experimental findings indicate that the HUCBCs transplantation is an effective and safe means for patients cardiogenic shock and severe heart failure after acute myocardial infarction.

BACKGROUND:Myocardial infarction patients commonly appear to have left ventricular remodeling and heart failure. Because of physical characteristics, these two complications are more likely to occur in elderly patients with myocardial infarction. In recent years, stem celltransplantation in the treatment of acute myocardial infarction and heart failure has become a hot topic, and the feasibility and safety has been confirmed, but its long-term outcomes in elderly patients are stil unclear.
OBJECTIVE:To assess the long-term effect of transplantation of autologous peripheral blood stem cells on the left ventricular remodeling and heart function in the old patients with myocardial infarction.
METHODS:Thirty old patients (age ≥ 60 years) with myocardial infarction were randomly assigned to receive intracoronary transplantation of peripheral blood stem cells fol owing bone marrow cells mobilization by granulocyte colony-stimulating factor ( 300-600μg per day) subcutaneously for 5 days in addition to conventional therapy (standard drug therapy and percutaneous coronary intervention;transplantation group, n=15) or standard therapy (standard drug therapy and percutaneous coronary intervention;control group, n=15) . Complications during intervention, left ventricular function and left ventricular remodeling at baseline and 6, 12, 24, 60 months after treatment were monitored.
RESULTS AND CONCLUSION:Left ventricular function, left ventricular end diastolic volume, and left ventricular end-systolic volume were significantly improved 6,12, 24, 60 months after autologous peripheral blood stem celltransplantation compared to baseline, while these parameters remained unchanged in the control group. These parameters had statistical difference between the two groups after treatment. During the fol ow-up, no severe side effects were observed. These findings indicate that autologous peripheral blood stem celltransplantation leads to significant and longstanding improvements in left ventricular performance of old patients with myocardial infarction, and shows good safety.

Objective:To establish an HPLC method for the determination of gallic acid,quercetin and kaempferol in Gongyanping capsules. Methods:HPLC was applied with the chromatographic conditions as follows: The chromatographic column was Agilent-SB C18 (250 mm × 4. 6 mm,5 μm) at 30℃; the mobile phrase was methanol-0. 3% phosphoric acid solution with gradient elution; the flow rate was 1. 0 ml·min-1. Results: The linearity relationship of gallic acid, quercetin and kaempferol was within the range of 98.200-491.00 μg·ml-1(r=0.999 9), 7.520-37.600 μg·ml-1(r=0.999 9) and 4.940-24.700 μg·ml-1(r=0.999 9), re-spectively;the average recovery was 96. 74%(RSD=1. 33%), 98. 18%(RSD=1. 70%) and 97. 04%(RSD=1. 28%),respective-ly. Conclusion:The method is simple, accurate and repeatable.

Objective To investigate effect of hs-CRP,IL-6, TNF-αand ICAM-1 in patients with coronary heart disease by Guanxinshengmaiyin. Methods 120 patients with coronary heart disease were selected and randomly divided into two groups.60 cases in control group were treated by routine treatment, 60 cases in experiment group were on the base of control group with Guanxinshengmaiyin,1 month for a course.hs-CRP, IL-6, TNF-αand ICAM-1 levels, clinical efficacy, electrocardiogram ( ECG ) and adverse reactions were compared after treatment.Results Compared with before treatment, hs-CRP, IL-6, TNF-αand ICAM-1 levels were lower(P<0.05).Compared with control group, the serum hs-CRP, IL-6, TNF-αand ICAM-1 levels were lower ( P<0.05 ) , the total efficiency ( 80.00%) was higher ( P<0.05 ) , the depth of T wave of lead II and lead III were lower (P<0.05),the adverse reactions occur rate was lower(P<0.05).Conclusion Guanxinshengmaiyin can reduce serum hs-CRP, IL-6, TNF-αand ICAM-1 levels in patients with coronary heart disease, and has good clinical curative effect, less adverse reaction.

Ambulatory blood pressure monitoring(ABPM)system can record patients blood pressure of 24 h on the predetermined time. The primary data forms the graph,the curve and the general report by operation of the related software after the analysis and statistics processing. Patients keep daily life condition,so the blood pressure data is more accuracy. ABPM can provide the dynamic change of the patients 24 h blood pressure,including the 24 h blood pressure survey data,the undulation situation and the change tendency. ABPM has become an useful element in the evaluation and follow - up of hypertension in adults. And ABPM is increasingly used to evaluate the blood pressure of children and adolescents in recent years. The ABPM has been shown to differ significantly values.

Objective This study was designed to evaluate the short-term effect and safety of 80 mg/d atorvastatin treating on ACS patients with interventional therapy in China. Methods From August 2002 to March 2014,1746 ACS patients accepting 80mg/d atorvastatin treatment were enrolled from three province hospital. All patients were divided into three groups, 886 patients in group A with 80mg/d atorvastatin treating for 4 weeks, 562 patients in group B with 80mg/d atorvastatin treating for 8 weeks, and 298 patients in group C with 80mg/d atorvastatin treating for 12 weeks after discharge. Blood lipid level, hepatic function, renal function and creatine kinase level were tested on 4th, 8th, 12th week. Results The percentage of patients reacting lipid levels was 85.0%in group A, 86.1%in group B, 94.0%in group C and 86.9%in total. The rate of ALT/AST exceed two times of normal upper level in group A was 1.6%, in group B was 1.8%and in group C was 1.0%.The symptom of joint and muscle pain in group A was 6.3%, group B was 1.4%, group C was 2.7%. The elevation of creatine kinase in group A was 0.8%, in group B was 0.5%, and 0%in group C. The symptom of abdomen discomfort in group A was 2.3%, group B was 2.5%and group C was 4.0%. The complaint of other symptoms was 3.2%in group A, 2.1%in group B, 1.7%in group C. Conclusions Accepting 80 mg/d atorvastatin treating for ACS patients with interventional therapy is effective and safe in short term.

Objective To evaluate CT findings and dynamic changes of post-traumatic intrapulmonary hematoma.Methods CT data of 43 patients with traumatic intrapulmonary hematomas were analyzed retrospectively.Results A total of 52 lesions were found in 43 patients with intrapulmonary hematomas.The majority of hematomas were located in the peripheral lung fields close to the pleura,single or multiple in number.CT showed nodular,mass,fusiform,ribbon and irregular shadows with uniform and high density in lung.There are two types of evolution: (1) The hematomas gradually reduced in size and finally disappeared;(2)The hematomas evolved into gas-liquid cyst cavity or gas cyst cavity, and then was absorbed gradually.Conclusion CT examination is helpful in the early diagnosis of post-traumatic intrapulmonary hematomas, and can monitor the morphology changes over time.

AIM: To observe the efficacy of intravitreal injection with ranibizumab combined with laser photocoagulation for macular edema ( ME ) secondary to macular branch retinal vein occlusion( MBRVO) .
METHODS:A retrospective analysis included 33 patients (33 eyes) with ME secondary to MBRVO were taken. All patients received intravitreal injection of 0. 5mg ranibizumab ( 0. 05ml ) at first visit. The continue PRN treatment and laser photocoagulation were based on the visual acuity changes and optical coherence tomography findings. The changes of best corrected visual acuity ( BCVA) , central macular thickness( CMT) , and amplitude density and latency of P1 wave in mfERG were observed before treatment and 6mo after treatment.
RESULTS: Before the treatment, logMAR was 0. 68±0.35, 6mo after treatment was 0. 34±0. 23, BCVA was improved obviously ( P < 0. 01 ), BCVA in 21 patients ( 63.64%) were improved in two rows among all the patients. CMT before treatment was(487. 30±63. 58) μm, after treatment was(238. 84±52. 66) μm(P<0. 01). The amplitude densities of P1 wave in ring 1, ring 2 and ring 3 after treatment were significantly increased(all P<0. 01), and the latencies were decrease ( all P < 0. 05 ). The conjunctival hemorrhage was observed in 2 eyes after treatment.
CONCLUSION: Intravitreal injection with ranibizumab combined with laser photocoagulation for ME secondary to MBRVO can reduce the CMT and improve visual function.

Objective: To investigate the effect of zinc sulfate and zinc methionine on growth and their possible regulating mechanism in mice. Method: Ninety male KM mice were randomly divided into three groups. The control group was fed on basal diet containing zinc of 11. 67 mg/kg 10d. The ZnSO4 group and Zn-Met group were fed on the diets supplemented with ZnSO4 or Zn-Met at 30 mg/kg(on the basis of Zn) for 10 d. Initial and final body weight,serum zinc concentration, growth hormone (GH),the levels of growth hormone receptor (GHR) and insulin like growth factor 1 (IGF-1) mRNA were determined. Results: Both ZnSO4 and Zn-Met enhanced body weight and serum zinc concentration of mice,Zn-Met more effectively than ZnSO4 for body weight . Both forms of zinc had no effect on GH and the expression of GHR mRNA , but both up-regulated the expression of IGF-1 mRNA. As compared to ZnSO4, Zn-Met enhanced the level of IGF-1 mRNA significantly. Conclusion: Both ZnSO4 and Zn-Met had no effect on GH and the expression of GHR Mrna,but enhanced the expression of IGF-1 mRNA. Zn-Met enhanced the body weight gain and up-regulated IGF-1 mRNA expression more effectively than ZnSO4.